^
Association details:
| Biomarker: | MELTF overexpression |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | SGN-CD228A (Microtubule inhibitor, CD228-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Published date:
04/03/2023
Excerpt:
In the squamous NSCLC model, a single dose of 1 or 3 mg/kg SGN-CD228A resulted in rapid tumor regression, producing durable remissions in 1/3 and 3/3 mice...SGN-CD228A was less active in NSCLC (26% ORR). However, in high CD228-expressing models, the ORR improved to 53% (n = 15) compared with 8% (n = 24) in low-expressing models.
DOI:
10.1158/1535-7163.MCT-22-0401
Source:
Title:
Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors
Excerpt:
We also evaluated antitumor activity of SGN-CD228A in melanoma and NSCLC xenograft and PDX models...Similarly, in the squamous NSCLC model, Calu-1, a single dose of 1.0 mg/kg produced 6/6 durable responses (DRs). Similar results were obtained in NSCLC PDX models with 3 out of 4 models achieving tumor delay or DRs when dosed with 1.0 mg/kg and durable (CRs) at 3.0 mg/kg...In summary, CD228 is a highly expressed carcinoma target and the novel glucuronide-MMAE ADC, SGN-CD228A, shows potent antitumor activity in vitro and in vivo.
DOI:
10.1158/1538-7445.AM2019-2688
